Answer
Yes, BeneFIX (nonacog alfa) carries a recognised risk of thrombosis and disseminated intravascular coagulation (DIC), requiring monitoring and benefit–risk assessment in patients with liver disease, postoperative patients, newborns, and those at risk of thrombosis or DIC.
Sources for this answer
- BeneFIX 250 IU powder and solvent for solution and injectionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 27Document updated
Sources checked